HEADLINES: • Hungary macro: MNB on hold • Cyfrowy Polsat: TiVi Foundation exercises its rights to replace the managers and a supervisory board member of the group POSITIVE • Medicover: 2Q25 results preview (due out tomorrow) • Tofas: 2Q25 earnings preview (due on 28 July) • Ford Otosan: 2Q25 earnings preview (due on 30 July) • Teknosa: 2Q25 earnings preview (due on 6 August) • Short News (EUR, 4iG, PPC)
HEADLINES: • EME Macro/Strategy: macro all-in-one (14-20 July) • OPAP: acquires remaining 15.5% stake in Stoiximan POSITIVE • Solutions by STC: 2Q25E financial results preview (due out tomorrow) • Borouge: 2Q25E results preview (due on 31 July) NEUTRAL • Grupa Pracuj: 2Q25E results preview – 3% yoy adjusted EBITDA growth expected (due on 28 August) • Erste Bank: 2Q25E preview (due on 1 August) • OTP Bank: 2Q25E preview (due on 5 August) • Bank Pekao: 2Q25E preview (due on 7 August) • PKO BP: 2Q2...
HEADLINES: • EME Macro/Strategy: macro all-in-one (7-13 July) • EU macro: US tariff announcement worse than expected • PKO BP: to book PLN 1.25bn of FX mortgage saga costs in 2Q25E NEUTRAL • Metlen Energy & Metals: MSCI to keep the stock in the Greece Standard index, as largely expected • Wirtualna Polska: 2Q25E preview – soft quarter, with 1% yoy pro-forma adjusted EBITDA growth expected (due on 26 August)
A director at Lenzing AG bought 18,180 shares at 27.630EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
We downgrade to Underperform (Neutral) and reduce our target price to € 20 (€ 33). Lenzing’s substantial investments, totaling more than € 3.3bn since 2017, increased the group’s net financial debt from € 119m in 2017 to € 2.0bn in 2024, while EBITDA fell by c. 20%. Lower volume demand, pricing pressure and high input costs led to a further increase of leverage (c. 5x 2024 net debt/EBITDA, excl. hybrid bond) and a massive earnings deterioration in 2022-24. Despite the capital increase in 2023, s...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.